Answers are grounded in this paper and cite their sources.
Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation. (Funded by Bristol-Myers Squibb; CheckMate 066 ClinicalTrials.gov number, NCT01721772.).
No takes yet. Share an insight, caveat, or question.
Robert et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: